Please login to the form below
Biogen
This page shows the latest Biogen news and features for those working in and with pharma, biotech and healthcare.
Innovate UK awards Sano Genetics £330,000 grant for ALS study
Participants will also have the opportunity to take part in new research studies as well as potentially take part in the testing of new therapies, including Biogen’s Qalsody (tofersen), the
Latest news
-
Biogen to acquire Reata for approximately $7.3bn
The deal gives Biogen access to a recently launched therapy for Friedreich's ataxia. ... Biogen has entered into a definitive agreement to acquire rare disease specialist Reata Pharmaceuticals for approximately $7.3bn.
-
Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Alzheimer’s Association International
-
BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn
Earlier this month, Biogen and Eisai’s Alzheimer’s disease drug Leqembi was granted traditional approval by the US Food and Drug Administration, making it the first and only approved
-
Biogen/Eisai’s Alzheimer’s disease drug granted full FDA approval
In a very welcome move, Biogen and Eisai’s Alzheimer’s disease drug has been granted traditional approval by the US Food and Drug Administration (FDA).
-
Biogen/Eisai’s Alzheimer’s drug backed by FDA advisory committee for traditional approval
Biogen and Eisai’s Alzheimer’s disease drug has been recommended for traditional approval by a US Food and Drug Administration (FDA) panel of experts. ... Christopher Viehbacher, president and chief executive officer of Biogen, said at the time: "The
More from news
Approximately 195 fully matching, plus 334 partially matching documents found.
Latest Intelligence
-
Can the patient pathway provide a route to success?
SMA testing is now included in many countries’ newborn screening programmes and the Alliance – which includes Novartis, Biogen and Roche as industry partners – has published a white paper calling for screening
-
After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream
Another example is Biogen’s $800m acquisition of Nightstar’s late-stage gene therapy assets for retinal disease – NSR-REP1 and NSR-RPGR.
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Alzheimer’s: the search for a cure
The whiplash turnaround is the result of Biogen’s analysis of data from two phase 3 trials. ... Baird analyst Brian Skorney is among the people who have a dim view of Biogen’s prospects.
-
20 for 2020 – Five pharma leaders to watch in 2020
Analysts think the deal could catapult Galapagos into the top tier of biopharma companies, joining the likes of Regeneron, Biogen and Roche’s Genentech unit, providing its pipeline delivers as hoped
More from intelligence
Approximately 2 fully matching, plus 46 partially matching documents found.
Latest appointments
-
VMLY&R Health appoints Natxo Diaz as global head of health craft
He has worked across a diverse range of therapeutic areas for clients including GSK, Pfizer, Novartis, Johnson &Johsnon, AstraZeneca, Gilead, Roche, Merck, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Takeda and Biogen.
-
BMS appoints new commercial leader, Davies joins Eisai and more
operations. She joins Sobi from Biogen, where she served as vice president for global supply chain operations and strategic partnerships.
-
Biogen appoints executive VP, corporate development
Biogen has appointed Daniel Karp as its executive vice president, corporate development effective 11 June. ... He said: “It's a privilege to join Biogen, a true leader in neuroscience," Karp said.
-
Gamida Cell strengthens leadership team
Nee will lead market research, analytics, forecasting, commercial strategies and competitive intelligence at the company, activities he has practised during his time with Biogen, Amgen and Novartis.
-
Editas Medicine names James Mullen as chairman
Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
More from appointments
Approximately 16 fully matching, plus 33 partially matching documents found.
Latest from PMHub
-
Viseven opens a new center of excellence in India
Biogen. Viseven enables an innovative governance model where a senior specialist is always involved in content production.
-
Mednet Group
Alzheimer’s Research UK. Alzheimer’s Society. Basic Needs. Biogen. Butterfly Scheme. Cardiomyopathy UK.
-
EPG Health
21Grams, Almirall, Alnylam, Amicus Therapeutics, AstraZeneca, Biogen, Boldscience, Caudex, Clinical Thinking, Convatec, CSL Behring, EMD Serono, GSK, Havas Lynx Group, In Vivo Academy, Ipsen, Janssen, Lupus UK, Merck, Novartis, Philips, Pfizer,
-
Article: Market access in Brazil
In April 2019, Brazilian Health Minister Luiz Henrique Mandetta announced a pilot agreement for access to Biogen’s Spinal Muscular Atrophy (SMA) treatment Spinraza (nusinersen) through the Sistema Único de Saúde
-
IGNIFI
Allergan. Biogen. Boehringer Ingelheim. CSL Behring. CSL Vifor. Danone Nutricia. Ferring Pharmaceuticals.
More from PMHub
Approximately 1 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
- EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer
- Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits
- Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
- MIT study reveals why certain immunotherapies do not always work
No results were found
PMHub
KVA
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
